DK1414837T3 - Adenosin A3-receptoragonister - Google Patents

Adenosin A3-receptoragonister

Info

Publication number
DK1414837T3
DK1414837T3 DK02763415T DK02763415T DK1414837T3 DK 1414837 T3 DK1414837 T3 DK 1414837T3 DK 02763415 T DK02763415 T DK 02763415T DK 02763415 T DK02763415 T DK 02763415T DK 1414837 T3 DK1414837 T3 DK 1414837T3
Authority
DK
Denmark
Prior art keywords
receptor agonists
adenosine
neutropennia
leukopenia
useful
Prior art date
Application number
DK02763415T
Other languages
English (en)
Inventor
Venkata Palle
Vaibhav Varkhedkar
Elfatih Elzein
Jeff Zablocki
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Application granted granted Critical
Publication of DK1414837T3 publication Critical patent/DK1414837T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
DK02763415T 2001-08-08 2002-08-06 Adenosin A3-receptoragonister DK1414837T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31106901P 2001-08-08 2001-08-08

Publications (1)

Publication Number Publication Date
DK1414837T3 true DK1414837T3 (da) 2005-11-07

Family

ID=23205248

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02763415T DK1414837T3 (da) 2001-08-08 2002-08-06 Adenosin A3-receptoragonister

Country Status (20)

Country Link
US (1) US20030078232A1 (da)
EP (1) EP1414837B1 (da)
JP (1) JP4357960B2 (da)
KR (1) KR100923888B1 (da)
CN (1) CN1244589C (da)
AT (1) ATE307136T1 (da)
AU (1) AU2002327426C1 (da)
CA (1) CA2456744A1 (da)
DE (1) DE60206775T2 (da)
DK (1) DK1414837T3 (da)
ES (1) ES2247371T3 (da)
HU (1) HUP0401437A3 (da)
IL (2) IL160231A0 (da)
MX (1) MXPA04001185A (da)
NO (1) NO327997B1 (da)
NZ (1) NZ530976A (da)
PL (1) PL368205A1 (da)
RU (1) RU2298557C2 (da)
WO (1) WO2003014137A1 (da)
ZA (1) ZA200401000B (da)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US7427606B2 (en) 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US7214665B2 (en) 2001-10-01 2007-05-08 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof
US7074801B1 (en) * 2001-04-26 2006-07-11 Eisai Co., Ltd. Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof
DE60330250D1 (de) * 2002-09-09 2010-01-07 Cv Therapeutics Inc Adenosin a3 rezeptor agonisten
WO2004086034A2 (en) * 2003-03-28 2004-10-07 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a3(adora3)
WO2005012256A1 (en) 2003-07-22 2005-02-10 Astex Therapeutics Limited 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
US7442687B2 (en) 2004-08-02 2008-10-28 The University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
WO2006028618A1 (en) 2004-08-02 2006-03-16 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
US20060194756A1 (en) * 2004-11-22 2006-08-31 Borea Pier A Enhancing treatment of HIF-1 mediated disorders with adenosine A3 receptor agonists
MX2007008781A (es) 2005-01-21 2007-09-11 Astex Therapeutics Ltd Compuestos farmaceuticos.
GB0505219D0 (en) * 2005-03-14 2005-04-20 Novartis Ag Organic compounds
CA2609117A1 (en) * 2005-05-19 2006-11-23 Cv Therapeutics, Inc. A1 adenosine receptor agonists
EP1883646A1 (en) * 2005-05-19 2008-02-06 Cv Therapeutics, Inc. A1 adenosine receptor agonists
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
WO2007047401A2 (en) * 2005-10-13 2007-04-26 Cv Therapeutics, Inc. A1 adenosine receptor agonists
US8178509B2 (en) 2006-02-10 2012-05-15 University Of Virginia Patent Foundation Method to treat sickle cell disease
US7589076B2 (en) * 2006-05-18 2009-09-15 Pgx Health, Llc Substituted aryl piperidinylalkynyladenosines as A2AR agonists
US8188063B2 (en) 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
DE102007012645A1 (de) 2007-03-16 2008-09-18 Bayer Healthcare Ag Substituierte Imidazo- und Triazolopyrimidine
US20100105705A1 (en) * 2007-03-28 2010-04-29 Neurosearch A/S Purinyl derivatives and their use as potassium channel modulators
MX2009010122A (es) 2007-03-28 2009-10-19 Neurosearch As Derivados de purinilo y su uso como moduladores del canal de potasio.
US20090088403A1 (en) * 2007-05-07 2009-04-02 Randy Blakely A3 adenosine receptors as targets for the modulation of central serotonergic signaling
EP2200615A1 (en) * 2007-10-16 2010-06-30 Gilead Palo Alto, Inc. A3 adenosine receptor antagonists
US8058259B2 (en) 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
RU2451010C1 (ru) * 2011-01-11 2012-05-20 Закрытое Акционерное Общество "Ива Фарм" Палладиево-медные катализаторы гомогенного селективного окисления тиольных групп, комбинация и композиция на их основе и способ терапевтического воздействия
CA2876780A1 (en) 2012-06-26 2014-01-03 Saniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
WO2014138485A1 (en) * 2013-03-08 2014-09-12 Irm Llc Ex vivo production of platelets from hematopoietic stem cells and the product thereof
WO2018212980A1 (en) * 2017-05-19 2018-11-22 Alltech, Inc. Pharmaceutical agents, compositions, and methods relating thereto
EP3988100A4 (en) * 2019-06-21 2023-07-26 Academy of Military Medical Sciences ADENOSINE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT OR ASSOCIATED STEREOISOMER, AND USE
AU2021413448A1 (en) * 2020-12-29 2023-07-20 Zhejiang Vimgreen Pharmaceuticals, Ltd Adenosine a3 receptor agonists, preparation methods and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180615B1 (en) * 1999-06-22 2001-01-30 Cv Therapeutics, Inc. Propargyl phenyl ether A2A receptor agonists
US6403567B1 (en) * 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
US6214807B1 (en) * 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists

Also Published As

Publication number Publication date
NZ530976A (en) 2005-07-29
DE60206775D1 (de) 2006-03-02
ZA200401000B (en) 2004-10-18
JP4357960B2 (ja) 2009-11-04
HUP0401437A2 (hu) 2004-11-29
EP1414837B1 (en) 2005-10-19
MXPA04001185A (es) 2005-06-17
AU2002327426B2 (en) 2007-06-14
NO20040969L (no) 2004-04-19
KR20040023733A (ko) 2004-03-18
EP1414837A1 (en) 2004-05-06
HUP0401437A3 (en) 2007-05-29
WO2003014137A1 (en) 2003-02-20
PL368205A1 (en) 2005-03-21
AU2002327426A2 (en) 2003-02-24
CA2456744A1 (en) 2003-02-20
JP2005501842A (ja) 2005-01-20
DE60206775T2 (de) 2006-07-20
NO327997B1 (no) 2009-11-09
RU2298557C2 (ru) 2007-05-10
IL160231A (en) 2010-11-30
ES2247371T3 (es) 2006-03-01
KR100923888B1 (ko) 2009-10-28
ATE307136T1 (de) 2005-11-15
RU2004106635A (ru) 2005-07-27
CN1538972A (zh) 2004-10-20
CN1244589C (zh) 2006-03-08
AU2002327426C1 (en) 2008-03-06
US20030078232A1 (en) 2003-04-24
IL160231A0 (en) 2004-07-25

Similar Documents

Publication Publication Date Title
DK1414837T3 (da) Adenosin A3-receptoragonister
CY1106424T1 (el) Παραγωγα ν-φαινυλ-πυρρολ γουανιδινης ως συνδετες υποδοχεις μελανοκορτινης
ATE293618T1 (de) 4, 5, 6, 7-tetrahydroindazolderivate als antitumormittel
ATE370120T1 (de) Substituierte 2-pyridin-cyclohexan-1,4- diaminderivate
ATE309245T1 (de) 5-amino-5-phenyl-7-cyclobutyl-pyrrolo(2,3- d)pyrimidin-derivate
NO20041917D0 (no) Spesifikke midler som binder humant angiopoietin-2
PT1444215E (pt) Derivados de 1,2,4-triadiazolio como moduladores do receptor de melanocortina
BR0208957A (pt) Ciclobuteno-1,2-dionas 3,4-dissubstituìdas como ligandos de receptor de quimiocina cxc
EA200301213A1 (ru) Лиганды рецепторов 5-ht и их применение
DE60225563D1 (de) 4-amino-6-phenyl-pyrroloä2,3-düpyrimidin derivate
PT1066269E (pt) Derivados de 1,3,5-triazina trissubstrituidos para o tratamento de infeccoes por hiv
PT1218378E (pt) Derivados de terc-butil-(7-metil-imidazo-¬1,2-a|-piridin-3-il)-amina
ATE360632T1 (de) Substituierte 8'-pyri(mi)dinyl-dihydrospiro- (cycloalkylamin)-pyrimido(1,2a)pyrimidin-6- onderivate
BR0207378A (pt) Tratamento de câncer
EA200601160A1 (ru) 2,6-бисгетероарил-4-аминопиримидины в качестве антагонистов аденозиновых рецепторов
MXPA04000886A (es) Derivados de triazolil-imidazopiridina y triazolilpurinas empledos como ligandos del receptor de adenosina a2a y su uso como medicamentos.
BR0215360A (pt) Derivados de indolina úteis como inibidores de proteìna quinase
DK1450811T3 (da) Forbindelser specifikke af adenosin A1- og A3-receptorer og anvendelser heraf
ATE358130T1 (de) Bicyclische (1,2,4ö-triazol adenosin a2a rezeptor antagonisten
DE602004024770D1 (de) Substituierte 8-perfluoro-6,7,8,9-tetrahydropyrimido-(1,2a) pyrimidin-4-on derivate
ATE418555T1 (de) A2a-adenosinrezeptorantagonisten
TR200201245T2 (tr) Kanser tedavisi için onkolitik kombinasyonlar.
DK1622908T3 (da) Xanthin-derivater som A2B adenosin-receptor-antagonister
CY1106194T1 (el) Θepαπευτικη αγωγη της δυσκινησιας
TR200102742T2 (tr) Rezorsinol türevleri